COVID-19: AstraZeneca likely provided an “incomplete view of efficacy data”

NIAID Statement on AstraZeneca Vaccine. National Institute of Allergy and Infectious Diseases (NIAID) – AstraZeneca likely provided an “incomplete view of efficacy data” on COVID-19 vaccine from a large scale U.S. trial  “Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review…